Karuna Therapeutics Inc KRTX:NASDAQ

Last Price$129.56NASDAQ Previous Close - Last Trade as of 1:00PM ET 11/26/21

Today's Change-5.09(3.78%)
Bid (Size)$121.77 (19)
Ask (Size)$140.18 (2)
Day Low / High$127.93 - 135.25
Volume101.1 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 11/26/2021

 

Karuna Therapeutics Inc ( NASDAQ )

Price: $129.56
Change: -5.09 (3.78%)
Volume: 101.1 K
1:00PM ET 11/26/2021
 
 

Apellis Pharmaceuticals Inc ( NASDAQ )

Price: $43.54
Change: -1.47 (3.27%)
Volume: 524.3 K
1:00PM ET 11/26/2021
 
 

Allakos Inc ( NASDAQ )

Price: $80.09
Change: -1.13 (1.39%)
Volume: 192.3 K
1:00PM ET 11/26/2021
 
 

Reata Pharmaceuticals Inc ( NASDAQ )

Price: $81.40
Change: -3.45 (4.07%)
Volume: 197.5 K
1:00PM ET 11/26/2021
 
 

Turning Point Therapeutics Inc ( NASDAQ )

Price: $39.30
Change: -2.38 (5.71%)
Volume: 271.4 K
1:00PM ET 11/26/2021
 

Read more news Recent News

Insider Sell: Karuna Therapeutics
1:17PM ET 11/11/2021 MT Newswires

Troy A. Ignelzi, Chief Financial Officer, on November 08, 2021, sold 13,500 shares in Karuna Therapeutics (KRTX) for $2,056,320. Following the Form 4...

Karuna Therapeutics, Zai Lab Enter Exclusive License Deal for Psychiatric Drug for Greater China
10:49AM ET 11/09/2021 MT Newswires

Karuna Therapeutics (KRTX) and Zai Lab (ZLAB) said Tuesday they have entered into an exclusive agreement for the development and commercialization of...

--Oppenheimer Adjusts Karuna Therapeutics PT to $175 From $148, Maintains Outperform Rating
9:55AM ET 11/08/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Adjusts Price Target for Karuna Therapeutics to $167 From $164, Maintains Outperform Rating
2:32PM ET 11/04/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionKaruna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. View company web site for more details
Address99 High Street
Boston, Massachusetts 02110
Phone+1.857.449.2244
Number of EmployeesN/A
Chairman, President & Chief Executive OfficerSteven Marc Paul
Chief Operating OfficerAndrew Miller
Chief Financial Officer & SecretaryTroy A. Ignelzi
Chief Medical OfficerStephen Brannan

Company Highlights

Price Open$133.14
Previous Close$134.65
52 Week Range$91.04 - 161.98
Market Capitalization$3.8 B
Shares Outstanding29.6 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.86
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-27.94%

Analyst Ratings as of 11/13/2021

Buy
14
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset